Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline

19 Aug 2026
MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the period ended June 30, 2026. H1 2026 key results Group performance 1: Double-digit revenue growth and gross margin
Read More

Telix HY26 Results Presentation

20 Aug 2026
Read More

Telix HY26 Results Announcement

20 Aug 2026
Read More

Telix HY26 Appendix 4D and Interim Report

20 Aug 2026
Read More

Telix to Host R&D Day in New York City on September 22, 2026

05 Aug 2026
MELBOURNE, Australia and INDIANAPOLIS, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today advises that it will host a Research and Development (R&D) Day on Tuesday, September 22, 2026, from 8:30 a.m. to 12:30 p.m. EDT in New York City.
Read More

Telix H1 2026 Results - Investor Webcast Notification

31 Jul 2026
Read More

Change in substantial holding

24 Jul 2026
Read More

TLX591-Tx ProstACT SELECT Study Published in Cancers Journal

21 Jul 2026
Peer-reviewed publication of ProstACT SELECT 1 results confirm the utility of 68 Ga (gallium)-PSMA-PET imaging to select patients for TLX591-Tx therapy using a theranostic approach 2. Consistent with previously reported results 3, the publication highlights TLX591-Tx’s clinical differentiation and
Read More

Q2 2026 Revenue US$247M Strong Momentum Pipeline Progress

21 Jul 2026
Read More

Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer

20 Jul 2026
First patient dosed in Phase 3 LUTEON 1 trial evaluating TLX250-Tx in relapsed or recurrent clear cell renal cell carcinoma (ccRCC). LUTEON is the first Phase 3 study of a CAIX 2 -targeted radiopharmaceutical therapy in ccRCC. MELBOURNE (Australia) and INDIANAPOLIS, July 21, 2026 (GLOBE NEWSWIRE)
Read More
Displaying 1 - 10 of 130